Lauren Buchanan, MA, Managing Editor

Alexandra Golant, MD, reviewed the complexities of managing atopic dermatitis with a focus on hand and foot involvement.

Explore dermatology's history and the journey through our publication's 45 years of covering an ever evolving specialty.

Matthew Zirwas, MD, hosted a Case-Based Roundtable discussion to review 2 challenging cases of atopic dermatitis involving intense itch and severe hand dermatitis.

A recent study offers a comprehensive analysis of practice patterns and patient characteristics in different clinical settings.

Explore evidence-based clinical recommendations for fireworks burns, chlorine irritation, and more.

A new report delves into the case of a 35-year-old man with ARPC and why dupilumab was utilized for treatment.

James Song, MD, shares a comprehensive guide to what is new, what is now, and what is next in AD treatment.

A recent study demonstrated the benefits and limitations of PatientsLikeMe for patients with atopic dermatitis and other skin conditions.

The treatment of vitiligo has advanced from ancient herbal remedies to the first FDA-approved topical, paving the way for improved management and outcomes.

Stefan Weiss, MD, MBA, explains next steps for the oral treatment after the completion of phase 1b enrollment.

Patricia Richey, MD, delves into efficacy of the 1927 and 1550 nanometer lasers to prevent skin cancers.

Sara Osborne, a fourth-year medical student and the lead author on the study, spoke with Dermatology Times on key findings and explain the need for further investigation.

Terry Arnold, PA-C, shares a wide range of opportunities to take clinical experience to a different setting and tips to transition.

Phase 3 clinical trial results showed that the safety and tolerability profiles were consistent with those observed in the original pivotal trials.

The primary efficacy endpoint is the proportion of subjects achieving at least a 50% improvement in the Facial Vitiligo Area Scoring Index.

Catch up on a weekend full of clinical pearls from the 2024 Fall Clinical Dermatology Conference for PAs and NPs in Scottsdale, Arizona.

Catch up on coverage from the last day of the 2024 Fall Clinical Dermatology Conference for PAs and NPs in Scottsdale, Arizona.

Jason Hawkes, MD, MS, detailed each of the kinases' association with different cytokine receptors and biological functions.

James Song, MD, explains combination treatment efficacy, addresses comorbidities, and provides pearls to improve patient safety.

Lockshin shared his approach to continuing biologic therapies into pregnancy with informed timing adjustments.

Jason Hawkes, MD, MS, breaks down boxed warning pros and cons and research addressing several boxed warnings.

The country's only double-board certified pediatric and cosmetic dermatologist shared what he learned from 5 unique patient cases this year.

James Song, MD, addressed current challenges in the AD treatment landscape and compared biologics.

Jason Hawkes, MD, MS, gives an overview of what clinicians need to know today about this rare condition.

Raj Chovatiya, MD, PhD, focused on understanding JAK inhibitors, discussing their clinical use and safety profiles for effective patient communication.

Catch up on coverage from the second day of the 2024 Fall Clinical Dermatology Conference for PAs and NPs in Scottsdale, Arizona.

Marc Serota, MD, provided clinical pearls to consider for patients on biologics, particularly dupilumab.

Raj Chovatiya, MD, PhD, takes a deep dive in the challenges, solutions, and further research needed to treat seborrheic dermatitis.

James Song, MD, discusses the current treatment landscape, genetic and immunological influences, and the role of oral minoxidil in alopecia areata.

Ben Lockshin, MD, FAAD, delves into the new generation of oral psoriasis therapies to enhance patient quality of life.